PreludeDx

Biotechnology ResearchUnited States51-200 Employees

PreludeDx was founded to deliver actionable tools to manage early stage breast cancer. 

PreludeDx's first diagnostic test, DCISionRT is the result of over a decade of research and development focused on DCIS. PreludeDx began developing its DCIS test in 2009 after licensing technology from University of California, San Francisco. DCISionRT’s technology was designed from the beginning to address the critical question faced by patients with DCIS. What is my risk of recurrence and what treatment is appropriate?

Sign up for free to view info

Email Format Employee directory